Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.
The current availability of a long-acting injectable formulation of risperidone and the potential future availability of long-acting formulations of other atypical antipsychotics (such as paliperidone) should prompt a reconsideration of at what stage in the treatment of schizophrenia such long-acting agents should be introduced. At present, long-acting formulations, particularly of conventional antipsychotics (depots), are usually reserved for patients with chronic schizophrenia who are at high-risk of noncompliance. Recent and increasing data from other patient groups, such as those with first-episode psychosis, suggest that long-acting risperidone is associated with good efficacy and tolerability leading to high patient acceptance, and treatment continuation rates that are greater than with oral antipsychotics. The benefits of an atypical antipsychotic coupled with the assurance of medication delivery in the form of a long-acting injection imply that these novel formulations should be considered in first-episode patients, for whom optimal outcome is frequently compromised by early treatment discontinuation and poor adherence.
Chue
Pierre
P
Department of Psychiatry, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. pchue@ualberta.ca
Emsley
Robin
R
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations